RUSCONI, STEFANO
RUSCONI, STEFANO
Dipartimento di Scienze Biomediche e Cliniche
11th European AIDS Conference, Madrid, Spain, 24-27 October 2007
2007-01-01 S. Rusconi
13th Conference on Retroviruses and Opportunistic Infections (CROI),DENVER, USA, 5-8
2006-01-01 S. Rusconi
14th conference on retroviruses and opportunistic infections, Los Angeles, CA, USA, 25-28 february 2007
2007-01-01 S. Rusconi
30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study
2020-01-01 A. Giacomelli, A.L. Ridolfo, L. Milazzo, L. Oreni, D. Bernacchia, M. Siano, C. Bonazzetti, A. Covizzi, M. Schiuma, M. Passerini, M. Piscaglia, M. Coen, G. Gubertini, G. Rizzardini, C. Cogliati, A.M. Brambilla, R. Colombo, A. Castelli, R. Rech, A. Riva, A. Torre, L. Meroni, S. Rusconi, S. Antinor, M. Galli
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation
2020-01-02 V. Di Cristo, F. Adorni, R. Maserati, M. Annovazzi Lodi, G. Bruno, P. Maggi, A. Volpe, P. Vitiello, C. Abeli, S. Bonora, M. Ferrara, M.V. Cossu, M.L. Oreni, E. Colella, S. Rusconi
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215
2000-01-01 S. Rusconi, S. La Seta Catamancio, F. Sheridan, D. Parker
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation
2007-01-01 C. Gervasoni, O. Vigano, E. Gianelli, M. Ortu, M. Galli, S. Rusconi
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral- experienced HIV-1-infected subjects treated with tenofovir combination therapy [2]
2005-10-01 M. Lo Cicero, E. Bulgheroni, F. Soster, O. Viganò, P. Cicconi, M. Galli, S. Rusconi
Accessibility to SARS-CoV-2 swab test during the Covid-19 pandemic : Did age make the difference?
2021-12-01 C. Trevisan, C. Pedone, S. Maggi, M. Noale, M. Di Bari, A. Sojic, S. Molinaro, A. Giacomelli, F. Bianchi, M. Tavio, S. Rusconi, G. Pagani, M. Galli, F. Prinelli, F. Adorni, R. Antonelli Incalzi
Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects
2002-02-01 S. Rusconi, E. Bulgheroni, S. La Seta-Catamancio, F.G. Croce, M. Lo Cicero, P.M. Citterio, M. Galli
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population
2020-01-01 E. Benetti, R. Tita, O. Spiga, A. Ciolfi, G. Birolo, A. Bruselles, G. Doddato, A. Giliberti, C. Marconi, F. Musacchia, T. Pippucci, A. Torella, A. Trezza, F. Valentino, M. Baldassarri, A. Brusco, R. Asselta, M. Bruttini, S. Furini, M. Seri, V. Nigro, G. Matullo, M. Tartaglia, F. Mari, F. Elisa, F. Chiara, D. Sergio, C. Susanna, A. Sara, F. Francesca, F. Montagnani, L. Di Sarno, A. Tommasi, M. Palmieri, A. Emiliozzi, M. Fabbiani, B. Rossetti, G. Zanelli, L. Bergantini, M. D'Alessandro, P. Cameli, D. Bennet, F. Anedda, S. Marcantonio, S. Scolletta, F. Franchi, M.A. Mazzei, E. Conticini, L. Cantarini, B. Frediani, D. Tacconi, M. Feri, R. Scala, G. Spargi, M. Corridi, C. Nencioni, G.P. Caldarelli, M. Spagnesi, P. Piacentini, M. Bandini, E. Desanctis, A. Canaccini, C. Spertilli, A. Donati, L. Guidelli, L. Croci, A. Verzuri, V. Anemoli, A. Ognibene, M. Vaghi, A. D'Arminio Monforte, E. Merlini, M.U. Mondelli, S. Mantovani, S. Ludovisi, M. Girardis, S. Venturelli, M. Sita, A. Cossarizza, A. Antinori, A. Vergori, S. Rusconi, M. Siano, A. Gabrieli, A. Riva, D. Francisci, E. Schiaroli, P.G. Scotton, F. Andretta, S. Panese, R. Scaggiante, S.G. Parisi, F. Castelli, M.E. Quiros-Roldan, P. Magro, C. Minardi, D. Castelli, I. Polesini, M. Della Monica, C. Piscopo, M. Capasso, R. Russo, I. Andolfo, A. Iolascon, M. Carella, M. Castori, G. Merla, F. Aucella, P. Raggi, C. Marciano, R. Perna, M. Bassetti, A. Di Biagio, M. Sanguinetti, L. Masucci, C. Gabbi, S. Valente, S. Guerrini, I. Meloni, M.A. Mencarelli, C.L. Rizzo, E. Bargagli, M. Mandala, A. Giorli, L. Salerni, G. Fiorentino, P. Zucchi, P. Parravicini, E. Menatti, S. Baratti, T. Trotta, F. Giannattasio, G. Coiro, F. Lena, D.A. Coviello, C. Mussini, A. Renieri, A.M. Pinto
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection
2021-01-01 L. Montefusco, M. Ben Nasr, F. D'Addio, C. Loretelli, A. Rossi, I. Pastore, G. Daniele, A. Abdelsalam, A. Maestroni, M. Dell'Acqua, E. Ippolito, E. Assi, V. Usuelli, A.J. Seelam, R.M. Fiorina, E. Chebat, P. Morpurgo, M.E. Lunati, A.M. Bolla, G. Finzi, R. Abdi, J.V. Bonventre, S. Rusconi, A. Riva, D. Corradi, P. Santus, M. Nebuloni, F. Folli, G.V. Zuccotti, M. Galli, P. Fiorina
AIDS in a long-term HIV-1-infected patient with a stable high CD4+ cell count and conserved CD4+CD45RO+ subpopulation
1996-12-01 C. Negri, S. Rusconi, A. Gori, C. Riva, C. Balotta, M. Galli
Alovudine Medivir
2003-02-01 S. Rusconi
Altered signaling lymphocytic activation molecule (SLAM) expression in HIV infection and redirection of HIV-specific responses via SLAM triggering
1999-09-01 L. Meroni, M. Fusi, S. Varchetta, M. Biasin, S. Rusconi, M. Villa, J. De Vries, G. Aversa, M. Galli, M. Clerici
Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro
1994-04-01 T. Mazzulli, S. Rusconi, D. P. Merrill, R. T. D'Aquila, M. Moonis, T. C. Chou, M. S. Hirsch
Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation
1999-07-01 S. Rusconi, S. La Seta-Catamancio, S. Kurtagic, M. Galazzi, D. Arienti, D. Trabattoni, J. Wilken, D. A. Thompson, R. E. Offord, M. Galli, M. Clerici
An update in the development of HIV entry inhibitors
2007-01-01 S. Rusconi, A. Scozzafava, A. Mastrolorenzo, C.T. Supuran
Analysis of protease inhibitor combinations in vitro : activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates
2004-03-01 E. Bulgheroni, P. Citterio, F. Croce, M. Lo Cicero, O. Viganò, F. Soster, T.C. Chou, M. Galli, S. Rusconi
Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol
2005-09-01 E. Bulgheroni, A. Bandera, M. Galli, A. Gori, S. Rusconi